Utah Medical Products Inc

Utah Medical Products Inc

  • Price (USD)94.12
  • Today's Change-2.35 / -2.44%
  • Shares traded4.10k
  • 1 Year change+6.35%
  • Beta0.1716
Data delayed at least 15 minutes, as of Feb 03 2023 21:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Utah Medical Products, Inc. (UTMD) is engaged in the business of producing medical devices that are predominantly differentiated by safety and improved patient outcomes. UTMD’s products include Blood Monitoring, which includes Deltran Disposable Blood Pressure Transducers, Deltran Plus Arterial Blood Sampling Systems, and Deltran Accessories; Electrosurgery, which includes Epitome Electrosurgical Scalpels, OptiMicro Ultra-Fine Tip Electrosurgical Needles, Finesse+ Electrosurgical Generators, Filtresse Surgical Smoke Evacuation Systems and Finesse+ Accessories; Labor and Delivery, which includes AROM-Cot, BT-Cath, CVX-Ripe, Intran, Muc-X and Cordguard; Neonatal Intensive Care, which includes Hemo-Nate, Thora-Cath, Nutri-Cath, Nutri-Lok, Myelo-Nate, Disposa-Hood, Neonatal Deltran, Pala-Nate, PICC-Nate, Dialy-Nate, Umbili-Cath and Uri-Cath; Urological Care, which includes the Liberty, Supra-Foley, and Pathfinder Plus; Womens Pelvic Health, and original equipment manufacturer/Capabilities.

  • Revenue in USD (TTM)--
  • Net income in USD--
  • Incorporated1978
  • Employees178.00
  • Location
    Utah Medical Products Inc7043 S 300 WestMIDVALE 84047United StatesUSA
  • Phone+1 (801) 566-1200
  • Fax+1 (801) 566-7305
  • Websitehttp://www.utahmed.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Eargo Inc34.39m-159.21m243.67m257.00------7.09-80.92-80.9217.48-18.430.21674.254.27133,817.10-100.31---343.16--30.57---462.95--0.6427-5.251.41---3.81---425.58------
Semler Scientific Inc54.43m12.62m261.97m124.0024.264.8819.794.811.581.586.767.850.9734.5514.24438,975.8022.5554.2926.0671.8690.3888.3823.1831.466.10--0.00--37.3648.1322.95--0.2688--
Tactile Systems Technology Inc234.61m-29.98m262.62m988.00--2.30--1.12-1.50-1.5011.745.680.94245.214.88237,462.50-12.041.80-14.592.1247.9548.68-12.781.461.68--0.30240.0011.1819.74-1,805.00--23.10--
SmileDirectClub Inc510.50m-93.82m272.64m3.20k--2.15--0.5341-0.7803-0.78034.240.32410.67263.692.93159,530.60-40.03---32.26--69.93---59.51--1.99-19.681.68---2.92---30.72------
Accuray Inc417.45m-11.82m281.34m1.04k--5.54--0.674-0.1265-0.12654.470.54190.88421.884.88399,851.50-2.500.4157-4.260.74437.2239.04-2.830.45550.98140.3230.77650.008.482.3215.27---2.54--
Orchestra Biomed Holdings Inc0.00-2.74m283.26m----1.65-----0.1855-0.18550.005.420.00-------2.38---2.40--------------0.00-------622.14------
ZimVie Inc946.34m-94.24m284.62m2.70k--0.38798.830.3008-3.61-3.6136.2728.130.55051.415.79350,497.00-5.48---6.24--62.76---9.96--1.48-7.690.4282--11.20--46.79------
Agape ATP Corp1.68m-1.93m302.56m36.00--135.44--180.13-0.0137-0.01370.01030.02960.40171.3094.7446,657.50-45.94---57.89--70.95---114.34--2.45-4.880.00---70.55---811.51------
Pulmonx Corp51.95m-57.65m329.58m253.00--2.02--6.34-1.56-1.561.414.370.23140.85187.35205,316.20-25.68---28.46--74.95---110.98--7.73-54.680.0961--47.91---50.98------
Utah Medical Products, Inc.-100.00bn-100.00bn341.43m178.00--2.99----------31.49------------------------14.10------------------
Vuzix Corp12.25m-47.02m366.50m106.00--2.92--29.91-0.738-0.7380.19231.970.08330.91455.36115,583.60-31.96-55.33-33.30-60.6917.482.36-383.75-280.3911.78--0.00--13.6743.98-101.80--17.29--
Edap Tms SA (ADR)57.60m3.85m393.26m227.00106.184.91--6.830.10250.10251.562.220.5983.344.22253,729.603.99-0.19235.02-0.288143.4543.556.68-0.24863.92--0.0661--5.774.35141.08-28.860.5449--
CVRx Inc22.47m-41.43m400.29m109.00--3.67--17.82-2.02-
AxoGen Inc133.96m-28.82m418.64m428.00--4.13--3.13-0.6882-0.68823.202.400.66071.536.71312,983.70-14.21-16.05-16.07-18.3680.2980.83-21.51-22.983.54--0.3097--13.4125.38-13.45--89.66--
SurModics, Inc.99.95m-27.27m423.07m447.00--3.88--4.23-1.96-1.967.187.730.56642.195.91223,604.00-15.45-2.06-18.74-2.4279.6583.39-27.29-3.571.43-55.800.0845---4.936.45-743.71---12.13--
Meihua International Medical Tech Co Ltd-100.00bn-100.00bn436.23m622.00--2.67----------5.93------------------------5.40--0.0375--16.82--10.00------
Data as of Feb 03 2023. Currency figures normalised to Utah Medical Products Inc's reporting currency: US Dollar USD

Institutional shareholders

49.47%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 30 Sep 2022380.09k10.48%
T. Rowe Price Investment Management, Inc.as of 30 Sep 2022342.19k9.43%
Renaissance Technologies LLCas of 30 Sep 2022216.51k5.97%
BlackRock Fund Advisorsas of 30 Sep 2022179.26k4.94%
The Vanguard Group, Inc.as of 30 Sep 2022160.71k4.43%
Dimensional Fund Advisors LPas of 30 Sep 2022152.92k4.22%
Rice, Hall, James & Associates LLCas of 31 Dec 2022114.37k3.15%
JPMorgan Investment Management, Inc.as of 30 Sep 202288.75k2.45%
Healthinvest Partners ABas of 30 Sep 202286.00k2.37%
Ranger Investment Management LPas of 30 Sep 202273.57k2.03%
More ▼
Data from 30 Sep 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.